Overview

A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

Status:
Completed

Trial end date:
2008-03-12

Target enrollment:

Participant gender:

Summary

Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.

Phase:

Phase 2

Details

Lead Sponsor:

Amicus Therapeutics